Marc Maliepaard
6PUBLICATIONS
9CO-AUTHORS
Get your video featured.
Publish with JoVEGet your video featured.
Publish with JoVE
Publications (6)
Sort by Publication Date:
|Feb 27, 2023
Reported hepatotoxicity and hepatotoxicity guidance in the product information of protein kinase inhibitors in oncology registered at the European Medicines Agency.Marc Maliepaard, Yoran S Faber, Mark T J van Bussel
|Jun 08, 2022
Impact of the new European Union In Vitro Diagnostics Regulation on the practice of hospital diagnostic laboratories.Audrey M M Hermans, Marc Maliepaard, Wouter P C Boon
|Jun 20, 2020
Pharmacokinetics and Generic Drug Switching: A Regulator's View.Pieter J Glerum, Cees Neef, David M Burger
|Apr 03, 2020
Pharmacogenetic-Pharmacokinetic Interactions in Drug Marketing Authorization Applications via the European Medicines Agency Between 2014 and 2017.Marc Maliepaard, Timi Toiviainen, Marie L De Bruin
|Jan 15, 2020
Ethnicity-Specific Drug Safety Data in European Medicines Agency Registration Dossiers, European Public Assessment Reports, and European and Singapore Drug Labels: Lost in Translation?Marc Maliepaard, Anne C Taams, Cynthia Sung
|Dec 06, 2019
Comment on "Levothyrox® New and Old Formulations: Are they Switchable for Millions of Patients?"Yang Yu, Marc Maliepaard
Pageof 1
Frequent Collaborators
2 joint publications
Yang Yu
1 joint publications
Anne C Taams
1 joint publications
Cynthia Sung
1 joint publications
Timi Toiviainen
1 joint publications
Marie L De Bruin
1 joint publications
Didier Meulendijks
1 joint publications
Wouter P C Boon
1 joint publications
Anna M G Pasmooij
1 joint publications
Mark T J van Bussel
